Abstract
There is scant literature available for pediatric prescribers regarding safety and efficacy of monoclonal antibody formulations against coronavirus disease 2019 (COVID-19). Here, we present 2 cases of serious infusion reactions in adolescent patients receiving the monoclonal antibody bebtelovimab and a succinct review of available antiviral medications for pediatric patients with mild or moderate COVID-19.
Author supplied keywords
Cite
CITATION STYLE
APA
Peters, M. E., Strayer, J., & Wald, E. R. (2023). Serious Infusion Reactions in Two Adolescents Receiving Bebtelovimab. Pediatric Infectious Disease Journal, 42(1), E1–E3. https://doi.org/10.1097/INF.0000000000003743
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free